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Background: Accumulating evidence suggests that the donor’s cause of death may
influence posttransplantation allograft function. We conducted a retrospective analy-
sis of our adult lung transplant experience to investigate the influence of donor trau-
matic brain injury versus nontraumatic brain injury on posttransplantation outcome.
Methods: We retrospectively reviewed donor records and recipient medical charts for
500 consecutive lung transplants performed between July 1988 and December 1999.
Recipient follow-up was complete, with a minimum follow-up of 1 year of survival.
Results: There were 295 and 205 donors in the traumatic and nontraumatic brain
injury groups, respectively. Young male donors predominated in the traumatic brain
injury group. Recipients receiving donor lungs from the traumatic and nontraumatic
brain injury groups did not differ by age, sex, diagnosis, type of transplant (single-
lung versus double-lung) or requirement for pretransplantation mechanical ventila-
tory assistance. Recipients did not differ in immediate or 24-hour PaO2/inspired
oxygen ratio, ventilation time, hospital stay, hospital mortality, or overall survival.
Recipients of organs from donors who died of traumatic brain injury showed a
higher severity and frequency of rejection episodes during the first year after trans-
plantation. Freedoms from bronchiolitis obliterans syndrome at 5 years were 34.5%
and 50.8% for recipients of organs from donors who died of traumatic and non-
traumatic brain injury, respectively (P = .002).
Conclusions: The cause of donor brain death does not appear to influence early
results of lung transplantation. Traumatic brain injury, or some phenomenon asso-
ciated with it, may predispose a transplanted lung and its recipient toward more
severe early rejection episodes and subsequent development of bronchiolitis oblit-
erans syndrome.
The insufficient supply of donor lungs results in prolonged waitingtimes and a substantial waiting list mortality among potential recip-ients. As a result of this donor shortage, lung transplant programsface intense pressure to use every possible donor lung. We have pre-viously suggested that marginal donor lungs can be used withoutcompromising early or late outcome.1,2 For the present, cadaveric
donors after brain death remain the major source of lung grafts. The effect of brain
death on pulmonary function is not clear, because knowledge of systemic changes
occurring after this catastrophic event remains limited. Recent data in the organ
transplant literature suggest that the donor’s cause of death may be a factor in deter-
mining outcome after transplantation.
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In the renal transplant literature, short- and long-term
function of transplanted kidneys from living donors is con-
sistently superior to that seen with kidneys from cadaveric
donors, which suggests that brain death may impact organ
function.3-5 Shivalkar and colleagues6 demonstrated that a
sudden rise in intracranial pressure resulted in poor func-
tional recovery of experimental heart grafts, and in some
cases this physiologic event was associated with irreversible
myocardial damage. Takada and associates7 observed
cytokine release and the activation of inflammatory cas-
cades in an explosive brain death model and suggested that
these events were responsible for changes in organ function.
In contrast, a multicenter study showed that death from
traumatic brain injury (TBI) had a positive influence on
allograft survival in cardiac and renal transplantation.8
There is conflicting information regarding the impact of
donor cause of death in the lung transplantation literature.
Waller and colleagues9 did not demonstrate a difference in
early graft function when the cause of donor death was clas-
sified as traumatic versus nontraumatic. On the other hand,
reports have demonstrated that transplantation of lungs con-
taining pulmonary embolic cerebral tissue after severe blunt
or penetrating donor head trauma may be associated with
increased recipient mortality.10,11
We performed this review to determine whether there was
an association between the cause of donor brain death and
clinical outcome after lung transplantation. We hypothesized
that this central catastrophe could lead to lung injury and
thus evoke a more intense host immunologic and inflamma-
tory response, with a higher tendency toward rejection.
Material and Methods
General
We conducted a retrospective review of 500 adult patients receiv-
ing lung transplants at Barnes Jewish Hospital between July 1988
and December 1999. Background characteristics of the recipients
are included in Table 1.
Donor Data
We recorded donor demographic characteristics, arterial blood gas
analysis, x-ray reports, and preremoval bronchoscopic results col-
lected from United Network for Organ Sharing records. We clas-
sified the cause of donor brain death as TBI or nontraumatic brain
injury (NTBI) according to cause of donor brain death recorded by
United Network for Organ Sharing donor charts. Spontaneous
intracranial hemorrhages and closed head injuries were the leading
causes of death in the NTBI and TBI groups, respectively.
Furthermore, we routinely categorized the donor groups into mar-
ginal or ideal groups according to previously published criteria.1
Donor Operation
The donor lung removal technique used by our team has been previ-
ously reported elsewhere.12 All 500 donors received broad-spectrum
antibiotics intravenously within a few hours before organ retrieval.
Donors were treated before organ removal with heparin (4 mg/kg
intravenously) and a bolus dose of prostaglandin E1 (500 µg) admin-
istered directly into the pulmonary artery immediately before aortic
crossclamping. Lungs were flushed with antegrade cold modified
Euro-Collins solution (60-80 mL/kg). In the last 3 years we have
administered pneumoplegia retrogradely into each pulmonary vein
with the same solution (5 mL/kg).13 In the last 2 years nitroprusside
at 10 mg/L has been added to the flush solution. Lungs were har-
vested en bloc, preserved for transport by immersion in cold saline
solution, and separated on return to our institution. Single-lung grafts
destined for different centers were divided at the donor hospital.
Recipient Data Collection
We recorded preoperative and postoperative recipient data from
recipient medical charts and our transplant database. Recipient fol-
low-up was complete for all patients who received transplants
through December 1999, with a minimum interval of 1 year for
surviving patients.
Recipient Criteria
Our standard recipient selection criteria have been previously pub-
lished elsewhere.14 Recipients are listed for transplantation when
TABLE 1. Patient characteristics
TBI (n = 295) NTBI (n = 205) P value
Donor age (y) 23.9 ± 9.3 33.4 ± 12.1 <.001
Donor sex (No.)
Female 70 (23.7%) 108 (52.7%) .001
Male 225 (76.3%) 97 (47.3%)
Donor race (No.)
White 236 (80.0%) 186 (90.7%) .001
Other 59 (20.0%) 71 (9.3%)
Donor CMV status (No.)
Negative 167 (56.6%) 130 (63.4%) .13
Positive 128 (43.4%) 75 (36.6%)
Recipient age (y) 46.6 ± 11.6 46.2 ± 12.1 .71
Recipient sex (No.)
Female 134 (45.4%) 113 (55.1%) .04
Male 161 (54.6%) 92 (44.9%)
Recipient diagnosis (No.)
Emphysema 153 (51.9%) 114 (55.4%) .14
Pulmonary hypertension 40 (13.6%) 16 (7.8%)
Cystic fibrosis 49 (16.6%) 30 (14.7%)
Pulmonary fibrosis 33 (11.9%) 22 (10.8%)
Other 20 (6.8%) 23 (11.3%)
Recipient time waiting (d) 515 (178-599*) 395 (235-695*) .001
Allograft type (No.)
Double-lung 191 (64.7%) 144 (70.2%) .06
Single-lung 103 (34.9%) 59 (28.9%)
Heart-lung 1 (0.4%) 2 (0.9%)
Ischemic time (min)
Right lung 290 ± 76.6 277.2 ± 81.4 .1
Left lung 313.9 ± 91.7 317.8 ± 89.7 .67
Cardiopulmonary bypass 71 (24.1%) 51 (24.9%) .83
*Interquartile range (25%-75%).
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they have disabling lung disease with a limited prognosis and no
other systemic illness that would complicate or be complicated by
lung transplantation and immunosuppression. All patients listed
for lung transplantation were enrolled in an active pulmonary
rehabilitation program, with the exception of patients with pul-
monary vascular disease.
Recipient Operative Technique and Postoperative Care
We have described our operative techniques previously else-
where.15,16 Early postoperative care was standardized. Mechanical
ventilation was discontinued when gas exchange and weaning pa-
rameters permit. Routine empirical perioperative antibiotics with
broad-spectrum gram-negative and gram-positive coverage was
administered. Subsequent antibiotic selection was based on the
results of donor and recipient bronchial cultures. Prophylaxis against
Pneumocystis carinii consisted of trimethoprim-sulfamethoxazole
given once daily until discharge, at which time the regimen was
changed to 3 times per week. Recipients with cytomegalovirus
(CMV) status mismatches carrying a high risk for infection (donor
CMV seropositive and recipient CMV seronegative) received intra-
venous ganciclovir prophylaxis for 12 weeks. All patients were mon-
itored for CMV viremia with weekly blood cultures.
A standard immunosuppressive protocol consisted of cyclo-
sporine, corticosteroids, and azathioprine. We used other agents,
including tacrolimus, mycophenolate mofetil, and sirolimus
according to the clinical course. Immunosuppression induction
typically included antithymocyte globulin. We performed routine
flexible bronchoscopy, bronchoalveolar lavage, and transbronchial
biopsies within 2 weeks and 3, 6, and 12 months, and on an as-
needed basis thereafter.
A diagnosis of acute rejection required pathologic confirma-
tion from a transbronchial biopsy specimen obtained during the
first year after transplantation. Rejection was graded according to
the grading system of the International Society for Heart-Lung
Transplantation.17 Severe acute rejection was deemed to be
present if any transbronchial biopsy specimen was graded A3 or
higher. Increased frequency of rejection was ascribed to those
patients with rejection scores of A2 or worse noted on 3 or more
biopsy specimens during the first year.18 Bronchiolitis obliterans
syndrome (BOS) was diagnosed and classified according to the
grading system devised by the International Society of Heart and
Lung Transplantation.19
Statistical Analysis
Normally distributed continuous data were expressed as mean ±
SD. Interquartile ranges were used when continuous data were
skewed. Categorical data were expressed as counts and propor-
tions. Unrelated two-group comparisons were done with unpaired,
2-tailed t tests for means of normally distributed variables and
with Wilcoxon rank sum tests for skewed data. The χ2 or Fisher
exact test was used to analyze differences among the categorical
data. Kaplan-Meier estimates were used to depict survivals and
freedoms from BOS. Survival and BOS-free survival comparisons
between groups of patients were completed with the Mantel-
Haenszel log-rank test.
Cox multivariate proportional hazards regression methods
were used to discriminate risk factors for development of BOS
after transplantation. The time to death and the time to diagnosis
of BOS were selected as the principal outcomes. All data analysis
was performed with Systat (Systat 7.0 for Windows; SPSS Inc,
Chicago, Ill). The regression models were constructed using
dependent variables known or suspected to be independent predic-
tors of the two outcomes based on previous published results and
the univariate differences observed between our two exposure
groups. The following categorical variables were considered: local
versus distant donor, marginal versus ideal donor, donor death
from TBI versus NTBI, donor sex, white versus nonwhite donor,
recipient sex, recipient diagnosis (emphysema, cystic fibrosis, pul-
monary hypertension, idiopathic fibrosis, other), single-lung ver-
sus double-lung transplant, recipient ventilator dependency at
transplantation, donor CMV status, CMV mismatch stratified
according to donor cause of death, presence of A3 rejection in
recipient, 3 or more versus less than 3 distinct bouts of A2 rejec-
tion, and lineal quartile of recipient in overall experience (first,
second, third, fourth).
The following continuous variables were considered: donor
age in years, time from injury to declaration of brain death, time
of declaration to procurement, recipient age in years, recipient
days on the waiting list, and ischemic time in minutes.
Results
Donor Characteristics
Two hundred ninety-five donors died as a result of TBI and
205 died as a result of NTBI. Other donor characteristics are
shown in Table 1. Our early experience appeared to use more
TBI donors, but the difference in the distribution of the two
groups was not significant (P = .07). There was no difference
between the TBI and NTBI cohorts with respect to recipient
age, diagnosis, type of transplant (single-lung versus double-
TABLE 2. Recipient outcome information
TBI (n = 295) NTBI (n = 205) P value
Acute
PaO2/inspired oxygen ratio
4-6 h* 321 ± 162.7 328 ± 166.6 .67
24 h* 210 ± 111.3 319 ± 119.2 .37
Mechanical ventilation (d) 2 (1-4†) 2 (1-4†) .35
Hospital stay (d) 18 (13-25†) 18 (13-25†) .35
Hospital mortality (No.) 25 (8.5%) 13 (6.3%) .39
Intermediate
A3 rejection‡ 59 (20.0%) 24 (11.7%) .02
A2 rejection ×3§ 49 (16.6%) 21 (10.2%) .02
CMV 71 (24.1%) 53 (25.9%) .67
*Time after crossclamp release and reperfusion of allograft.
†Interquartile range (25%-75%).
‡One or more episodes of pathologically graded A3 rejection determined
by transbronchial biopsy within first year after transplantation.
§Three or more episodes of pathologically graded A2 rejection or greater
determined by transbronchial biopsy within first year after transplantation.
One or more episodes of pathologically diagnosed CMV pneumonitis
determined by transbronchial biopsy within first year after transplantation.
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lung versus heart-lung transplantation) or requirement for
pretransplantation mechanical ventilatory assistance.
Recipient Characteristics
Pretransplantation waiting list time was significantly differ-
ent between TBI and NTBI recipients. There was also a sta-
tistically significant difference in recipient sex, with a
higher rate of male patients receiving lungs from TBI
donors (Table 1).
Recipient Operation
Three hundred thirty-five patients underwent double-lung
transplantation, 162 patients underwent single-lung trans-
plantation, and 3 patients received heart-lung grafts. For
TBI and NTBI recipients there was no statistically signifi-
cant difference in the ischemic time, nor in the use of car-
diopulmonary bypass during the transplantation procedure
(Table 1).
Postoperative Results
Univariate analysis revealed comparable postoperative out-
comes in the groups, with no significant difference in
immediate or 24-hour PAO2/inspired oxygen ratio, length of
mechanical ventilation, length of hospitalization, or hospi-
tal mortality (Table 2). However, TBI recipients showed a
higher severity and frequency of rejection episodes in the
first year after transplantation (Table 2). Five-year survivals
were 52.2% and 53.4% for TBI and NTBI recipients,
respectively (P < .8; Figure 1).
Kaplan-Meier estimates of freedom of BOS at 5 years
were 34.5% and 50.8% for TBI and NTBI recipients, respec-
tively (P = .002; Figure 2). Cox proportional hazards analy-
sis of risk factors for death did not result in any independent
risk factors, and the overall model lacked statistical signifi-
cance. The results of the Cox multivariate analysis of risk
factors for the development of BOS after transplantation are
shown in Table 3. TBI and the occurrence of A3 rejection in
the first year after transplantation were statistically signifi-
cant risk factors for development of BOS. Recent timing of
transplantation was a negative risk factor for BOS.
Discussion
Cadaveric donors after brain death will remain the major
source of lung grafts for the foreseeable future. Brain death
can be associated with injury to organs intended for trans-
plantation.3,4 In fact, the irreversible loss of brain function
will probably lead to a progressive deterioration in function
of all organs. Interest has recently focused on the physio-
logic changes occurring during brain death, although the
mechanism of the subsequent systemic changes remains
unclear.5 Explosive brain death results in significant hemo-
dynamic alteration and upward regulation of proinflamma-
tory mediators and cell-surface molecules in donor organs.
Experimental studies have demonstrated that a sudden
increase in intracranial pressure leads to a series of patho-
physiologic changes that have been described as “auto-
nomic storm” and are characterized by catecholamine
release and histopathologic changes in potentially trans-
plantable organs.20,21 Hemodynamic changes include
increased systemic vascular resistance and increased mean
arterial pressure, with acute elevation of left atrial pressure.
Pulmonary capillary integrity may be disrupted, resulting in
Figure 1. Kaplan-Meier survival plot of percentages of patients
alive after transplantation stratified by donor cause of death as
TBI (vertical lines) or NTBI (open circles). Percentages and num-
bers of patients available for analysis at each year are shown
below graph.
Figure 2. Kaplan-Meier survival plot of percentages of patients
free from BOS after transplantation stratified by donor cause of
death as TBI (vertical lines) or NTBI (open circles). Percentages
and numbers of patients available for analysis at each year are
shown below graph.
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acute pulmonary edema. Endocrine changes in epinephrine,
cortisol, and thyroxine levels increase organ damage as aer-
obic metabolism is progressively inhibited. Brain injury
enhances the effects of cytokines and other alloantigen-
independent factors that play a role in subsequent allograft
chronic rejection, such as humoral activity and mononu-
clear cell infiltration.22
Despite the numerous differences between TBI and NTBI
donors, our data do not support the hypothesis that donor
cause of death affects recipient survival. Furthermore, we
could not detect an immediate difference between these
groups of recipients in their physiologic outcomes after
transplantation. However, TBI recipients did appear to have
a higher severity and frequency of acute rejection episodes
within 1 year after transplantation. The risk of development
of BOS was higher among our TBI recipients than among
our NTBI recipients. The increased risk for BOS among
TBI recipients appeared to be independent of the additional
risk caused by severe acute rejection.
Various factors have been associated with increased risk
for subsequent BOS, including CMV infection, frequency
and severity of early lung allograft rejection episodes,
biopsy findings of lymphocytic bronchiolitis, increased
donor age, increased ischemic time, the development in the
recipients of donor-specific anti-HLA antibodies during
postoperative course, and type of transplant (single-lung vs
double-lung transplant).18,23 We evaluated many of these
risk factors by including them in our Cox model assessing
risk factors for BOS. The inclusion of donor age, recipient
age, ischemic time, frequency of acute rejection, and trans-
plant type as independent variables did not affect the rela-
tive risk for BOS attributable to TBI in our data.
There are a number of limitations to this retrospective
review. First, we acknowledge the possibility that TBI is
associated with BOS without causing it. For this to be true
there must be some other factor closely associated with both
TBI and BOS. We reported a higher number of male
patients in the TBI donor group and a higher number of
male patients receiving TBI grafts. Presumably, this
inequity is due to the fact that TBI donors are more often
male because males more often are affected by trauma.
Male recipients are more likely to receive male donor lungs
because of the size issues, and therefore male recipients,
male donors, and TBI donors are linked more than chance
would dictate. We do not think that donor or recipient sex
can have a role in our finding of TBI as associated with
BOS, however, because no previous reports have suggested
that donor or recipient sex is a risk factor for BOS.
Novick and coworkers24 have suggested that older donor
age is associated with increased risk for BOS. With respect
to the donor age, we found that TBI donors were younger
than were NTBI donors; however, this group still had an
increased incidence of subsequent BOS.
There may be other covariates that were unmeasured and
perhaps unevenly distributed between our TBI and NTBI
groups. TBI donors are usually given a higher number of
blood transfusions or blood products which could actually
render the graft at a higher level of antigenicity. The evalu-
ation of the TBI donor is complicated by the fact that the
resuscitation and stabilization of such donors are less con-
trolled. The TBI donors may have a higher incidence of
aspiration of gastric contents at the time of injury which in
turn may produce subsequent gram-negative infections.
Circumstances of endotracheal intubation may differ, as
TBI donors are more likely to be intubated at the scene of
the accident, potentially in a less sterile environment. Donor
hypotension and donor lung contusion could be other fac-
tors expected to cause tissue damage and could thus predis-
pose the TBI lungs to an increased risk of BOS. Because
these factors are unmeasured potential causes of lung injury
that are likely to be unequally distributed between the TBI
and NTBI groups, they remain as potential confounders in
this analysis.
There is also a possibility that TBI is involved in a causal
pathway that leads to BOS. In fact, previous work in other
organs have demonstrated end-organ damage as a result of
TBI and have emphasized that different causes of brain
death may produce different somatic effects. This same
mechanism may lead to pulmonary damage and set in
motion a chain of events leading to an escalated host
response to the graft lungs.
Furthermore, we have to consider that the differences
seen here were due to chance alone. We have arbitrarily
divided a group of 500 patients into groups on the basis of
a single exposure criterion and then compared the exposure
TABLE 3. Multivariate Cox proportional hazards model of
risk factors for BOS after transplantation
Variable No. Relative risk 95% CI P value
A3 rejection episode* 83 2.115 1.550-2.886 <.001
Donor TBI 295 1.432 1.078-1.900 .013
Time of transplantation
1st quartile (reference) 125 1 — —
2nd quartile 125 0.836 0.609-1.149 .27
3rd quartile 125 0.553 0.374-0.816 .003
4th quartile 125 0.272 0.160-0.462 <.001
Primary diagnosis
Emphysema (reference) 267 1 — —
Pulmonary fibrosis 55 0.916 0.599-1.401 .687
Cystic fibrosis 79 1.307 0.914-1.869 .142
Pulmonary hypertension 56 1.197 0.780-1.837 .411
Other 43 0.85 0.491-1.470 .56
*One or more episodes of pathologically graded A3 rejection determined
by transbronchial biopsy within first year after transplantation.
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groups on the basis of numerous (20) criteria. By chance
alone we would expect them to differ in at least 1 or 2 cri-
teria at a level of significance of P < .05.
The possibility also exists that donors or recipients have
been misclassified according to exposure status (TBI vs
NTBI) or outcome status (BOS or death). The exposure sta-
tus was straightforward and not subjective, because donor
cause of death was provided by the United Network for
Organ Sharing from records created at the time of trans-
plant. The end point of death is also unequivocal, but that of
BOS is less certain. It is certainly possible that the most
recent cohort of transplant recipients have been underdiag-
nosed for BOS simply because of the periodic, scheduled
nature of the surveillance bronchoscopies. Because TBI
donors were more prevalent during the early experience,
such an oversight in recent recipients would lead to overes-
timation of the BOS risk caused by TBI. Although this is
possible, the inclusion of the quartile variable in the Cox
regression model should account for differences in the BOS
risk in early versus late recipients.
We are also reluctant to accept that TBI is associated
with a higher risk for BOS while not being associated with
a higher risk for death. The plausibility of the association
between TBI and BOS is weakened by the reported finding
that BOS remains the leading cause of late complications
and mortality after lung transplantation. The patient sample
size is large and the effect size of BOS risk is moderate, but
the consistency that must be seen to accept the association
is lacking. We therefore accept our findings as an
exploratory observation in need of confirmation.
Conclusions
Our study demonstrated equivalent early outcomes and no
significant difference in long-term survival between TBI
and NTBI groups. However, TBI was associated with sever-
ity of acute rejection and development of BOS. Whether
recipients whose donors have died of TBI need a closer sur-
veillance or earlier intensification of immunosuppression
therapy warrants verification with further studies to provide
the clinical relevance of this fascinating finding.
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Discussion
Dr John V. Conte (Baltimore, Md). This is an interesting arti-
cle that looked at the largest number of donors and the impact of
traumatic and nontraumatic injuries on outcomes to date. The
results have the advantage, unlike other articles, of long-term fol-
low-up, which I think adds a lot. Dr Ciccone, you mentioned that
in your TBI group the largest percentage of donors died of blunt
head injury. Did you have the opportunity perhaps to look at those
who had projectile or open-head injury types as opposed to the
blunt head injury? Might that have had any impact on the out-
comes? A second and related question is whether you have had the
opportunity to look at the time from injury until brain death and
see whether that had any impact on outcomes. You hypothesized in
your article that part of the injury was caused by the explosive
release of inflammatory mediators, and perhaps it should be the
impact of the time that the donor was exposed to these mediators,
as opposed to the mechanism of release of these mediators, that
might have the effect.
On another note, you appropriately did a Cox analysis and
pointed out some of the factors that have been associated with
BOS. There have been other factors through the years that have
been associated, less convincingly than the ones you looked at,
and I was wondering whether you looked at such factors as reper-
fusion injury and the incidence of diffuse alveolar disease among
the lung biopsy specimens that you retrieved to see whether there
was any correlation there.
Also, did you go back and do retrospective crossmatch or ret-
rospective HLA analyses of the donors and recipients, particularly
the HLA-DR locus, to see whether there was any impact on those
variables? And did you look at all types of infection, not just CMV
infection? That was the only infectious agent that you mentioned
in the article.
Finally, you mentioned that it might be a good idea to look at
this group of patients a little bit more closely. Have you changed
your surveillance bronchoscopy schedule on these patients, and
have you changed your immunosuppressive management of these
patients as a result of the findings in this study?
Dr Ciccone. Dr Conte, please repeat your first question.
Dr Conte. Did you look at the different types of TBI, closed-
head injury versus open-head injury, for example, from a gunshot
wound?
Dr Ciccone. We did not subcategorize types of TBI. We
divided the time from injury to harvest and we divided from injury
to declaration of death and declaration of death to harvest. Of
course, the time from injury to declaration of death was shorter in
the TBI group than in the NTBI group, and this was the time where
we found a statistical difference. There was no difference in the
time from declaration of death to lung removal.
We included in our regression analysis 30 separate variables
(including ischemic reperfusion injury and diffuse alveolar dam-
age) that we did not report to avoid overloading the article with too
many data. None of these resulted in a statistically significant dif-
ference. This was also true for CMV status. We did not look at the
HLA matching.
Your last question concerns our current treatment program. At
this time we have not changed surveillance or immunosuppression
of patients receiving lungs from donors who died of TBI, because
we are unsure of the clinical relevance of this fascinating finding.
However, we think that this finding warrants verification with
other programs’ experience and may provide insight into the fac-
tors leading to BOS. In this regard, all of us know that any infor-
mation is helpful.
Dr Malcolm M. DeCamp, Jr (Cleveland, Ohio). I continue to
be fascinated by the whole mechanism of brain death and early
posttransplantation outcome, as our heart transplant experience
from the Cleveland Clinic found just the opposite, that hearts from
donors who died of trauma had better survival than did those from
donors who died of nontraumatic causes. So this is clearly an area
that needs to be further investigated.
I had one question regarding CMV status. I noticed that there
was no difference in CMV status between the TBI and NTBI
donors. How about the CMV mismatch issue of positive donor
organs into seronegative recipients, which has been implicated as
leading to problems with chronic rejection?
Finally, could you just comment on your routine immunosup-
pressive regimen? Induction regimens have been shown to
decrease the risk of early acute rejection or at least severe acute
rejection, though they have not shown a survival advantage. It
would appear that you saw a little bit more grade III or severe
rejection in this TBI group. Thus this might be an ideal group to
consider varying immunosuppression on the basis of the mecha-
nism of brain death of the donor.
Dr Ciccone. The analysis that we presented documents donor
CMV status only. As you point out, there was no difference in
CMV status between TBI and NTBI donors. We have not yet com-
pleted the analysis of donor-recipient CMV mismatch for these
groups. Recipients with CMV status mismatches that carry high
risk for infection (donor CMV positivity and recipient CMV neg-
ativity) receive intravenous ganciclovir prophylaxis for 12 weeks.
All patients are monitored for CMV viremia with weekly blood
cultures. I did not understand your last question about the severity
of the acute rejection.
Dr DeCamp. You reported an increased incidence of severe
rejection in the TBI group than in the NTBI group, although it did
not appear to make a difference in terms of survival. Induction
therapy, for what it’s worth, has been shown to decrease both the
incidence and the severity of acute rejection, although these dif-
ferences have not translated into a survival advantage. Would you
consider the use of induction immunotherapy for recipients of
organs from donors who died of TBI?
Dr Ciccone. As I previously stated, we have not changed any
of our treatment at the moment. Our belief is that these patients are
already heavily immunosuppressed with our current regimen. Our
standard immunosuppressive protocol consists of cyclosporine,
corticosteroids, and azathioprine. Other agents, including
tacrolimus, mycophenolate mofetil and sirolimus, are used as sec-
ond line drugs depending upon clinical course. Historically we
have used antithymocyte globulin as induction therapy. However,
in recent months we have been using basiliximab in cases of CMV
mismatch with seronegative recipients.
Dr Axel Haverich (Hannover, Germany). We are yet left with
no answer as to the BOS syndrome in the TBI subgroup. At least
in Europe most of those who have TBI have also a lot of injuries
in other places. They are often operated on for peripheral bleeding
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or for abdominal bleeding. Have you looked into the number of
blood transfusions or blood products, which are usually not given
in cases of NTBI death? Blood products could actually place the
graft at a higher level of antigenicity and therefore would be able
to explain both the higher incidence of acute rejection and also
BOS. So have you looked at the number of blood transfusions in
the two groups?
Dr Ciccone. Dr Haverich, you raise a potentially important
question. When we began this review, we attempted to examine the
influence of donor blood transfusion on outcome. However, this
analysis was impossible because the data were missing for many
donors in our early experience.
Dr Michael F. McGrath (Norfolk, Va). Obviously donors
come from a number of different kinds of hospitals and settings.
Were you able to split out those patients who had early neurosur-
gical intervention to decompress the rapid rise in intracranial pres-
sure and see whether that had any effect on the donor lungs?
Dr Ciccone. No, we did not include this in our analysis.
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